Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward V Loftus

Showing results (451-460 of 471) with videos related to

Pageof 48
Sort By:
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.
Inflammatory Bowel Diseases|March 2, 2013
Challenges in IBD research: update on progress and prioritization of the CCFA's research agendaLee A Denson, Millie D Long, Dermot P B McGovern, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Inflammatory Bowel Diseases|May 12, 2011
Development of the Crohn's disease digestive damage score, the Lémann scoreBenjamin Pariente, Jacques Cosnes, Silvio Danese, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 29, 2025
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical PracticeBénédicte Caron, Vipul Jairath, Bruce E Sands, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Journal of Crohn'S & Colitis|September 19, 2025
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trialsMariangela Allocca, Vipul Jairath, Bruce E Sands, et al.
Pageof 48

Showing results (451-460 of 471) with videos related to

Sort By:
Pageof 48
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.
Inflammatory Bowel Diseases|March 2, 2013
Challenges in IBD research: update on progress and prioritization of the CCFA's research agendaLee A Denson, Millie D Long, Dermot P B McGovern, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Inflammatory Bowel Diseases|May 12, 2011
Development of the Crohn's disease digestive damage score, the Lémann scoreBenjamin Pariente, Jacques Cosnes, Silvio Danese, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 29, 2025
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical PracticeBénédicte Caron, Vipul Jairath, Bruce E Sands, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Journal of Crohn'S & Colitis|September 19, 2025
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trialsMariangela Allocca, Vipul Jairath, Bruce E Sands, et al.
Pageof 48